Browse > Article
http://dx.doi.org/10.4014/jmb.1407.07002

Soluble Expression and Purification of Receptor Activator of Nuclear Factor-Kappa B Ligand Using Escherichia coli  

Park, Sol-Ji (Department of Food Science and Technology, Sunchon National University)
Lee, Se-Hoon (Department of Pharmacy, Sunchon National University)
Kim, Kwang-Jin (Department of Pharmacy, Sunchon National University)
Kim, Sung-Gun (Department of Biomedical Science, Youngdong University)
Kim, Hangun (Department of Pharmacy, Sunchon National University)
Choe, Han (Department of Physiology and Bio-Medical Institute of Technology, University of Ulsan College of Medicine)
Lee, Sang Yeol (Department of Life Science, Gachon University)
Yun, Jung-Mi (Department of Food and Nutrition, Kwangju Women's University)
Cho, Jae Youl (Department of Genetic Engineering, Sungkyunkwan University)
Chun, Jiyeon (Department of Food Science and Technology, Sunchon National University)
Choi, Kap Seong (Department of Food Science and Technology, Sunchon National University)
Son, Young-Jin (Department of Pharmacy, Sunchon National University)
Publication Information
Journal of Microbiology and Biotechnology / v.25, no.2, 2015 , pp. 274-279 More about this Journal
Abstract
Receptor activator of nuclear factor-kappa B ligand (RANKL) is a critical factor in osteoclastogenesis. It makes osteoclasts differentiate and multinucleate in bone remodeling. In the present study, RANKL was expressed as a soluble maltose binding protein (MBP)-fusion protein using the Escherichia coli maltose binding domain tag system (pMAL) expression vector system. The host cell E. coli DH5α was cultured and induced by isopropyl β-D-1-thiogalactopyranoside for rRANKL expression. Cells were disrupted by sonication to collect soluble MBP-fused rRANKL. The MBP-fusion rRANKL was purified with MBP Trap affinity chromatography and treated with Tobacco Etch Virus nuclear inclusion endopeptidase (TEV protease) to remove the MBP fusion protein. Dialysis was then carried out to remove binding maltose from the cleaved rRANKL solution. The cleaved rRANKL was purified with a second MBP Trap affinity chromatography to separate unsevered MBP-fusion rRANKL and cleaved MBP fusion protein. The purified rRANKL was shown to have biological activity by performing in vitro cell tests. In conclusion, biologically active rRANKL was successfully purified by a simple two-step chromatography purification process with one column.
Keywords
RANKL; osteoclast; purification; chromatography; E. coli;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.   DOI   ScienceOn
2 O’Brien CA, Nakashima T, Takayanagi H. 2012. Osteocyte control of osteoclastogenesis. Bone 54: 258-263.   DOI   ScienceOn
3 Smith DM, Nance WE, Kang KW. 1973. Genetic factors in determining bone mass. J. Clin. Invest. 52: 2800-2808.   DOI   ScienceOn
4 Wardlaw G. 1988. The effects of diet and life-style on bone mass in women. J. Am. Diet. Assoc. 88: 17-25.
5 Willard D, Chen WJ, Barrett G, Blackburn K, Bynum J, Consler T, et al. 2000. Expression, purification, and characterization of the human receptor activator of NF-KB ligand (RANKL) extracellular domain. Protein Expr. Purif. 20: 48-57.   DOI   ScienceOn
6 Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272: 25190-25194.   DOI   ScienceOn
7 Xiong J, Charles AO. 2012. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res. 27: 499-505.   DOI
8 Ilich JZ, Kerstetter JE. 2000. Nutrition in bone health revisited: a story beyond calcium. J. Am. Coll. Nutr. 19: 715-737.   DOI
9 Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.   DOI   ScienceOn
10 Boyce BF, Xing L. 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473: 139-146.   DOI   ScienceOn
11 Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50.   DOI   ScienceOn
12 Gallagher JC, Riggs BL, Eisman J. 1994. Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 90: 646-650.
13 Grigoriades AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.   DOI
14 Jeong TH, Son YJ, Ryu HB, Koo BK, Jeong SM, Hoang P, et al. 2014. Soluble expression and partial purification of recombinant human erythropoietin from E. coli. Protein Expr. Purif. 95: 211-218.   DOI   ScienceOn
15 Kanamaru F, Iwai H, Ikeda T, Nakajima A, Ishikawa I, Azuma M. 2004. Expression of membrane-bound and soluble receptor activator of NF-kappa B ligand (RANKL) in human T cells. Immun. Lett. 94: 239-246.   DOI   ScienceOn
16 Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, et al. 2006. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells. Mol. Cell. Biol. 26: 1002-1013.   DOI   ScienceOn